Calypte Biomedical to Host 2nd Quarter Conference Call PLEASANTON, Calif., Aug. 10 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC:CYPT) (BULLETIN BOARD: CYPT) announced today that it will host a conference call on Thursday August 12th 2004, at 11:00 a.m. EDT. The call will outline the results of the second quarter and six months ended June 30, 2004. Dial in numbers for the conference call are as follows. Investors in the U.S. and Canada interested in participating in the conference call may dial 800-435-1261 and reference the Calypte Biomedical call. International investors may dial 617-614-4076. A live webcast of the conference call including a slide presentation will be available for investors by accessing the Company's website at http://www.calypte.com/ and clicking on "Investors." A replay will be available through August 24, 2004 by calling 888-286-8010. International callers should dial 617-801-6888 for the replay. The replay confirmation code is 60270956. About Calypte Biomedical: Calypte Biomedical Corporation, headquartered in Pleasanton, California, is a public healthcare company dedicated to the development and commercialization of in vitro diagnostic tests, primarily for the detection of antibodies to Human Immunodeficiency Virus (HIV), and other sexually transmitted and infectious diseases. Calypte's currently marketed laboratory- based tests include an enzyme immunoassay (EIA) HIV-1 antibody screening test and an HIV-1 antibody western blot supplemental test, the only two FDA-approved HIV-1 antibody tests for use on urine samples, as well as an FDA-approved serum HIV-1 antibody western blot supplemental test. Calypte is actively engaged in developing new test products for the rapid detection of HIV and other infectious diseases. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other infectious diseases may make important contributions to public health. Company Contact: Investor Relations Contact: Richard Brounstein, CFO Tim Clemensen, (925) 730-7200 Rubenstein Investor Relations Email: Phone: 212-843-9337 Email: DATASOURCE: Calypte Biomedical Corporation CONTACT: Company Contact - Richard Brounstein, CFO of Calypte Biomedical Corporation, +1-925-730-7200, ; Investor Relations Contact - Tim Clemensen of Rubenstein Investor Relations, +1-212-843-9337, , for Calypte Biomedical Corporation Web site: http://www.calypte.com/

Copyright